LP
FOLD

LMR Partners’s Amicus Therapeutics FOLD Stock Holding History

LMR Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,700
Closed -$138K – 1609
2025
Q4 		$138K Buy
+9,700
New +$95.3K ﹤0.01% 1318

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

LMR Partners's FOLD Position: Q1 2026 in Review

LMR Partners reduced its Amicus Therapeutics (FOLD) stake by 9.3% in Q1 2026, selling an estimated $1.54M and leaving 1,049,700 shares worth $15.2M. The position accounts for 0.03% of the portfolio, ranked #286.

LMR Partners first reported a position in FOLD in Q2 2014 and has held it in 5 quarters since. The position peaked at $16.5M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • LMR Partners held 1,049,700 shares of Amicus Therapeutics worth $15.2M as of Q1 2026.
  • LMR Partners sold 107,500 Amicus Therapeutics shares in Q1 2026, an estimated $1.54M.
  • Amicus Therapeutics made up 0.03% of LMR Partners's portfolio in Q1 2026, its #286 holding.
  • LMR Partners first reported a position in Amicus Therapeutics in Q2 2014 and has held it in 5 quarters since.
  • LMR Partners's Amicus Therapeutics position peaked at $16.5M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.